About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Anti-Cancer Drugs
›
Top Articles
Anti-Cancer Drugs
Oncology
,
Pharmacology
2.4
(top 7%)
Impact Factor
2.6
(top 7%)
extended IF
90
(top 4%)
H-Index
1.7K
authors
4.2K
papers
73.1K
citations
4.8K
citing journals
41.2K
citing authors
Most Cited Articles of Anti-Cancer Drugs
Title
Year
Citations
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
1996
628
Drug-polymer conjugates: potential for improved chemotherapy
1992
398
Dendrimer-platinate
1999
370
PI3K/Akt/mTOR pathway as a target for cancer therapy
2005
354
A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs
2009
301
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
2007
273
Triterpenoids as new promising anticancer drugs
2009
259
Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines
1997
258
Histone deacetylase inhibitors in cancer treatment
2002
255
Liposomal encapsulated anti-cancer drugs
2005
250
Targeting Stat3 in cancer therapy
2005
229
Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience
1995
217
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
2001
215
Preclinical characteristics of gemcitabine
1995
206
Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines
1996
205
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study
2009
193
NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent
2006
192
Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
1995
191
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
1997
184
Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays
1995
183
Mitomycin C
1990
174
Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer
1997
173
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status
2008
165
Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly
2003
161
Gemcitabine--a safety review
1998
160
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.